TMCI Earnings Prediction
The chart below shows how TMCI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TMCI sees a +4.44% change in stock price 10 days leading up to the earnings, and a -6.39% change 10 days following the report. On the earnings day itself, the stock moves by -1.31%. This data can give you a slight idea of what to expect for the next quarter's release.
TMCI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
45.09M
10.62%
1.42%
Gross Margin
80.14%
-0.30%
-0.14%
Operating Margin
-33.57%
-23.22%
-30.21%
Net Margin
-34.07%
-20.75%
-28.57%
EPS
-0.25
-10.71%
-26.47%
No Data Available
TMCI Earnings Analysis
Treace Medical Concepts, Inc. Common Stock Corporation (TMCI.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: Third quarter revenue was $45.1 million, representing an 11% growth over the prior year period.
Gross Margin Stability: Gross margin was 80.1% in the third quarter of 2024 compared to 80.4% in the third quarter of 2023, indicating stable profitability.
Operating Expenses Management: Total operating expenses were $51.3 million in the third quarter of 2024, reflecting effective cost management strategies.
Adjusted EBITDA Improvement: Adjusted EBITDA loss in the third quarter was $5.1 million, an improvement of 45% compared to the loss of $9.2 million in Q3 2023.
2024 Revenue Guidance Update: We are revising our full year 2024 revenue guidance to $204 million to $211 million, reflecting an increase of 9% to 13% over 2023 revenue.
Negative
Slower Revenue Growth: Third quarter revenue was $45.1 million, representing an increase of only 11% over the prior year period, indicating slower growth compared to previous quarters.
Gross Margin Decline: Gross margin decreased to 80.1% in the third quarter of 2024 compared to 80.4% in the third quarter of 2023, reflecting a decline in profitability.
Operating Expenses Increase: Total operating expenses increased to $51.3 million in the third quarter of 2024 from $50.6 million in the third quarter of 2023, indicating rising costs that could impact future profitability.
Quarterly Net Loss Comparison: Third quarter net loss was $15.4 million or $0.25 per share compared to a net loss of $17.5 million or $0.28 per share for the same period of 2023, showing ongoing financial challenges despite a smaller loss.
EBITDA Loss Improvement: Adjusted EBITDA loss in the third quarter was $5.1 million, an improvement of only 45% compared to the loss of $9.2 million in Q3 2023, suggesting that the company is still struggling to achieve profitability.
TMCI FAQs
How does TMCI typically perform around its earnings report dates?
Is Treace Medical Concepts, Inc. (TMCI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TMCI Earning Call Sentiment
Treace Medical Concepts, Inc. (TMCI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TMCI.O
-1.5%Positive
The earnings call reflects a mixed outlook. While Treace Medical shows positive financial performance with revenue growth and improved EBITDA, challenges like regulatory risks and competitive pressures remain. The absence of clinical data for new products raises concerns, but management's optimistic guidance and strategic initiatives could counterbalance these. The lack of a shareholder return plan and slight gross margin decline further contribute to a neutral sentiment. The Q&A reveals uncertainty about future growth, with management avoiding clear guidance for 2025. Overall, the stock price is likely to remain stable in the short term.